Tucson, AZNCT04062565Now EnrollingIRB Ready

Pulmonary Arterial Hypertension Clinical Trial in Tucson, AZ

Access cutting-edge pulmonary arterial hypertension treatment through this phase 3 clinical trial at a research site in Tucson. Study-provided care at no cost to qualified participants.

Sponsored by University of Arizona

Quick Self-Assessment

See if you qualify for this Tucson location

Preparing your pre-screening questions…

Expert Care in Tucson

Access pulmonary arterial hypertension specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pulmonary arterial hypertension treatment provided free

Apply for This Tucson Location

Check if you qualify for this pulmonary arterial hypertension clinical trial in Tucson, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Tucson

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Tucson site if eligible
  4. 4Begin participation

About This Pulmonary Arterial Hypertension Study in Tucson

The purpose of this study is to determine if there is a greater effect to patients with advanced pulmonary arterial hypertension (PAH) by using a combination of two drugs, Treprostinil and Riociquat versus Treprostinil alone

Sponsor: University of Arizona

Who Can Participate

Inclusion Criteria

WHO Category I PAH
Resting mPAP ≥ 25 mmHg with a wedge pressure of ≤ 15mmHg during right heart catheterization.
Need for parenteral TRE as determined by the PH specialist caring for the patient

Exclusion Criteria

Patients with a mean arterial pressure \<60, and/or requiring vasopressor support
Patients whom expected device (i.e. ECMO, RVAD) assistance or early pulmonary transplantation (within 3 months) seems inevitable
Patients with a left ventricular ejection fraction \<50% or clinical, echocardiographic, and/or catheterization data consistent with heart failure with preserved ejection fraction (HFpEF) and/or moderate-severe aortic or mitral valve abnormality
Patients with severe restrictive lung disease (FVC\<70% predicted) and/or obstructive lung disease (FEV1 \<70% predicted and FEV1/FVC \<70%).
Patients with a history of pulmonary embolism within the last three months or evidence of chronic pulmonary embolism.
Patients with a known contraindication to right heart catheterization.
Patients whom have received active or previous pulmonary vasoactive medication within the previous 12 weeks.
PAH associated with significant venous or capillary involvement (PCWP \> 15 mmHg), known pulmonary veno-occlusive disease, and pulmonary capillary hemangiomatosis.
Pulmonary Hypertension belonging to groups 2 to 5 of the WHO classification.
Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C.
Estimated creatinine clearance \< 30 mL/min
Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 1.5 times the upper limit of normal.
Hemoglobin \< 75% of the lower limit of the normal range.
Acute or chronic physical impairment (other than dyspnea), limiting the ability to comply with study requirements.
Pregnant or breast-feeding.
Females must either abstain from intercourse (when it is in line with their preferred and usual lifestyle), or
Use 2 medically acceptable, highly effective forms of contraception for the duration of study, and at least 30 after discontinuing study drug.
Known concomitant life-threatening disease with a life expectancy \< 12 months.
Body weight \< 40 kg and/or \>150 kg.
Any condition that prevents compliance with the protocol or adherence to therapy.
Concurrent therapy with strong CYP3A4 inhibitors/inducers (i.e. protease inhibitors, azole antibiotics, macrolides), theophylline, and any medication in the PI's opinion may substantially potentiate the hypotensive effect of RIO.
Treatment with nitrates of any kind within the 4 weeks prior to enrollment.
Known hypersensitivity to drugs of the same class as TRE and/or RIO, or any of their excipients.
Planned treatment, or treatment, with another investigational drug within 1 month prior to randomization.
Recent (\<6 months) hemoptysis and/or history of severe hemoptysis requiring intervention (bronchial artery embolization).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Tucson?

Yes, this clinical trial (NCT04062565) has an active research site in Tucson, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pulmonary Arterial Hypertension Treatment Options in Tucson, AZ

If you're searching for pulmonary arterial hypertension treatment options in Tucson, AZ, this clinical trial (NCT04062565) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Tucson research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced pulmonary arterial hypertension specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pulmonary arterial hypertension clinical trials near you to find additional studies recruiting in your area.

More Hypertension Trials in Tucson, AZ

See all hypertension clinical trials recruiting in Tucson — not just this study.

Browse Hypertension Trials in Tucson →

Browse More Trials by Condition

Hypertension TrialsPulmonary Embolism TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Tucson?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Tucson, AZ